United States 119th Congress Status: In Committee Bipartisan · 1 D · 1 R cosponsors

HR 4139 — Cutting Copays Act

Last action — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the House. Introduced June 25, 2025. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the House.

Odds of enactment

Low chance

Based on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Advancing 34% · moderate confidence

  • In Committee

    Current position in the legislative process.

  • 2 sponsors

    1 primary, 1 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 2 parties (1 D · 1 R) — cross-party backing.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

In plain language

HR 4139 aims to address key energy and commerce issues.

This bill has been introduced in the House and is currently under review by relevant committees. It addresses important matters within the energy and commerce sectors.

Summary

Cutting Copays ActThis bill eliminates cost-sharing for generic drugs for those with the lowest-income under the Medicare prescription drug benefit's Low-Income Subsidy Program beginning in 2026.

Bill Text

How this bill changes current law

2 changes Share ↗

Compared against current U.S. Code AI-generated reading aid — verify against the official bill.

The bill amends the Social Security Act to adjust cost-sharing reductions for low-income individuals under Medicare Part D.

  • 42 U.S.C. 1395w-114(a)

    that does not exceed $1 for → that does not exceed-- ``(I) for plan years before plan year 2026-- ``(aa) for a generic drug or a preferred drug that is a multiple source drug (as defined in section 1927(k)(7)(A)(i)), $1 or, if less, the copayment amount applicable to an individual under clause (iii); and ``(bb) for any other drug, $3 or, if less, the copayment amount applicable to an individual under clause (iii); and

    This change modifies the maximum copayment amounts for certain drugs under Medicare Part D for low-income individuals.

  • 42 U.S.C. 1395w-114(a)

    ``(II) for plan year 2026-- ``(aa) for a generic drug, $0; and ``(bb) for any other drug, the dollar amount applied under this clause (after application of paragraph (4)(A)) for plan year 2023 for a drug described in subclause (I)(bb); and ``(III) for a subsequent year, the dollar amount applied under this clause for the previous year for the drug, increased by the annual percentage increase in the consumer price index (all items; U.S. city average) as of September of such previous year.''.

    This addition specifies new copayment amounts for generic and other drugs for plan year 2026 and subsequent years, including adjustments based on the consumer price index.

Action History

  1. Introduced in House

  2. Introduced in House

  3. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  4. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 1 co-sponsors · 545 not signed on

Sponsors (1)

Co-sponsors (1)

Not signed on (545)

545 members have not signed on to this bill.

Show all 545 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HR 4139 do?
Cutting Copays ActThis bill eliminates cost-sharing for generic drugs for those with the lowest-income under the Medicare prescription drug benefit's Low-Income Subsidy Program beginning in 2026.
Who sponsors HR 4139?
HR 4139 is sponsored by Bilirakis, Gus M. (Republican) and McGarvey, Morgan (Democratic).
What is the current status of HR 4139?
This bill is in committee in the House. Introduced June 25, 2025. It must pass committee before a floor vote.
Where can I track HR 4139?
Track HR 4139 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HR 4139

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HR 4139

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →